Blockbuster patent expirations, fewer drugs in the pipeline, rising number of generics, and regulatory pressures are causing the pharmaceutical industry to question the fundamentals
on which they have relied. A paradigm shift is occurring in which pharmaceutical companies must realign marketing competencies to realize opportunities of existing and evolving product lines.
DIA and HMC will collaborate to present this marketing and sales conference by senior level management from large- and mid-size pharmaceuticals, joined by leading healthcare and educational affiliates who will deliver leading practices for applying drug development synergies to maximize brand value and leverage mid-size markets to produce similar blockbuster results.